8-K: VBI Vaccines Extends Forbearance Agreement with Lenders Amidst Financial Covenant Breach

VBI Vaccines has extended its forbearance agreement with K2 HealthVentures for a fifth time, now through February 6, 2024, due to a failure to meet minimum net revenue covenants.

Summary

• VBI Vaccines and its subsidiary, VBI Cda, have extended their forbearance agreement with K2 HealthVentures and other lenders for the fifth time.
• The forbearance agreement was initially entered into on November 13, 2023, due to the company's failure to meet the minimum net revenue covenant for the period ended September 30, 2023.
• The forbearance period has been extended multiple times, with the latest extension pushing it to February 6, 2024.
• The company's ability to meet the conditions of the forbearance agreement is not assured, and failure to do so could lead to its termination.
• The forbearance agreement does not waive the company's obligation to meet the loan agreement covenants, and K2HV could declare an event of default after the forbearance period.
• If an event of default occurs, K2HV can demand immediate payment of all obligations, stop further credit extensions, and increase the interest rate by 5.00% per annum.

Sentiment

Score: 3

Explanation: The document indicates significant financial distress and uncertainty, with a high risk of loan default. The repeated extensions of the forbearance agreement and the potential for increased interest rates paint a negative picture.

Negatives

• VBI Vaccines has failed to meet its minimum net revenue covenant, triggering the need for a forbearance agreement.
• The company's financial situation is precarious, with the risk of loan default and increased interest rates.
• There is no guarantee that the company will meet the conditions of the forbearance agreement.
• The lender could declare an event of default after the forbearance period.

Risks

• The company may not be able to meet the conditions of the forbearance agreement, leading to its termination.
• K2HV could declare an event of default after the forbearance period, resulting in immediate repayment of all obligations.
• An event of default would also lead to a 5.00% per annum increase in the interest rate.
• The company's financial stability is at risk due to the breach of loan covenants.

Future Outlook

The company's ability to meet the conditions of the forbearance agreement is uncertain, and there is a risk of loan default if the conditions are not met. There is no assurance that the company would be able to enter into another forbearance agreement for any additional periods.

Management Comments

• Jeffrey R. Baxter, President and Chief Executive Officer, signed the report on behalf of VBI Vaccines Inc.

Industry Context

This announcement highlights the financial challenges faced by some biotechnology companies, particularly those reliant on debt financing. The inability to meet revenue targets and subsequent reliance on forbearance agreements is not uncommon in the sector, especially for companies in the development stage.

Comparison to Industry Standards

• Many biotech companies, especially those pre-revenue or with limited product sales, rely on debt financing and face similar challenges in meeting financial covenants.
• Companies like Novavax and Ocugen have also faced financial difficulties and have had to restructure debt or seek additional funding.
• The specific terms of the loan agreement and the minimum revenue targets are unique to VBI Vaccines, making direct comparisons difficult, but the general situation of struggling to meet financial obligations is not uncommon in the industry.

Stakeholder Impact

• Shareholders face increased risk due to the company's financial instability and potential loan default.
• Employees may be concerned about the company's future and job security.
• Creditors face the risk of non-payment if the company defaults on its loan obligations.

Next Steps

• The company needs to meet the conditions of the forbearance agreement by February 6, 2024.
• The company may need to seek alternative financing or restructure its debt if it cannot meet the conditions of the forbearance agreement.

Key Dates

Keywords

forbearance agreement, loan agreement, net revenue, default, K2 HealthVentures, financial covenant, VBI Vaccines, lenders